MetSyn is a probiotic complex by SynBalance, specifically designed for metabolic syndrome.
It has been tested in a randomized, double-blind, controlled clinical trial on 60 subjects diagnosed with metabolic syndrome. After 14 days of run-in, in which subjects were asked to improve their lifestyle, the probiotic and placebo supplements were administered for 2 months. Patients were evaluated by physical, laboratory, hemodynamic analyses and by Quality of Life questionnaire (EuroQol- 5 Dimension – EQ-5D) at T0 and T60 (end of the study).  They were randomized to be treated with a combination of three specific probiotic strains Lactobacillus plantarum PBS067, Lactobacillus acidophilus PBS066 and Lactobacillus reuteri PBS072 to evaluate whether their metabolic and inflammatory parameters were positively influenced with respect to placebo.
Results after two months showed a significant (p<0.05) global reduction of circumference of the waist, visceral adipose index, levels of triglycerides, LDL cholesterol and fasting plasma insulin compared to baseline and placebo. HDL cholesterol showed a significant improvement versus baseline and placebo (p<0.05).
In addition, there was a significant decrease of hsCRP protein (p<0.05) which is known to be a marker of systemic inflammation that predicts the risk of developing cardiovascular diseases and it is closely associated to abdominal obesity, metabolic syndrome, and atherosclerotic cardiovascular disease. Together with hsCRP, there was also a reduction of Tumor Necrosis Factor alpha (TNF-α), the principal cytokine involved in the rising of inflammation (p<0.05).
At the end of the study, the number of patients diagnosed with metabolic syndrome was strongly reduced (-23%) in the active group with respect to placebo (-10%) pinpointing that the sole improvement of life style is not enough to overcome this condition, but a multiple approach is recommended.

Scientific reference(s)

Cicero, Arrigo FG, et al. "Impact of a short term synbiotic supplementation on metabolic syndrome and systemic inflammation in elderly patients: a randomized placebo controlled clinical trial." European journal of nutrition (2020).
The most performin strain have been selected though different specific in-vitro models, as the downregulation of inflammation and the modulation of the enzymes involved in lipid and carbohydrates metabolism

Additional info

Therapeutical area(s)



Anti-inflammatory activity · Cholesterol management



Dosage form



6 billion(s)
Scroll to Top